Mark Cuban warned that many employers are collecting drug rebate money funded by their sick employees — a practice that can ...

Americans largely trust their doctors but are skeptical of payers, drugmakers and hospital leadership — a divide fueled by ...

The U.K. cost-effectiveness standard for drugs will increase by 25% in exchange for zero tariffs on the country’s ...

Despite today’s technological advancements, a large amount of prior authorization requests are submitted via fax machine. A new partnership between Blue Shield of California and Salesforce will ...

This week, medical device giant Abbott announced its plans to acquire Bigfoot Biomedical. The deal is not that surprising given that the two companies have been collaborating for more than six years, ...

One in six American youth experience a mental health disorder each year. In California, about a third of adolescents experienced serious psychological distress between 2019 and 2021. In that same time ...

Abbott and Medtronic are typically regarded as competitors, but the two medical device giants have recently decided to join forces. Last week, the two companies teamed up to collaborate on a ...

A Travere Therapeutics drug that won speedy approval early this year for a rare autoimmune kidney disorder has failed to meet the key goal of its confirmatory study. Still, the biotech points to data ...

Twin brothers Xing and Yang Su have shaped their careers around each other and have long wanted to start a company together. As they were deciding what to build, their three living grandparents — who ...

Nearly all leaders in the healthcare industry have a shared understanding that while AI will never replace workers’ lived clinical judgment, the technology can provide them with much-needed respite ...

As employers brace for significant healthcare cost increases in 2026, many are seeking out innovative strategies to manage the impact. This comes from the Business Group on Health’s newly released ...

Pancreatic cancer continues to be one of the most difficult-to-treat cancers. An Ipsen drug is now approved as a first-line therapy, moving it up in the treatment hierarchy for this type of cancer.